Zevra therapeutics announces resubmission of arimoclomol new drug application to the u.s. food and drug administration

Celebration, fla., dec. 27, 2023 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) a rare disease therapeutics company, today announced it resubmitted its new drug application (nda) for arimoclomol, an investigational therapeutic candidate for the treatment of niemann-pick disease type c (npc) to the u.s. food and drug administration (fda) on december 22, 2023. based on standard nda resubmission review timelines, an acknowledgment letter from the fda that the resubmission is complete and setting the pdufa date is expected within 30 days. zevra expects the nda to be classified as a class ii submission which would be subject to a review period by the fda within six months from the date of submission.
ZVRA Ratings Summary
ZVRA Quant Ranking